24 assets in Urinary Bladder Neoplasm

Therapeutic assets addressing Urinary Bladder Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Urinary Bladder Neoplasm	Merck Sharp & Dohme LLC	P2	BB (71)
Cis-Diamminedichloroplatinum Ii Urinary Bladder Neoplasm	Merck Sharp & Dohme LLC	P2	BB (68)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Urinary Bladder Neoplasm	Eli Lilly and Company	P2	BB (68)
Pembrolizumab Urinary Bladder Neoplasm	Eli Lilly and Company	P2	BB (66)
Nivolumab Urinary Bladder Neoplasm	Ikena Oncology	P2	B (60)
Capecitabine Urinary Bladder Neoplasm	Merck Sharp & Dohme LLC	P2	B (57)
Docetaxel Urinary Bladder Neoplasm	Merck Sharp & Dohme LLC	P2	B (57)
Fluorouracilum Urinary Bladder Neoplasm	Merck Sharp & Dohme LLC	P2	B (57)
Lenvatinib Urinary Bladder Neoplasm	Merck Sharp & Dohme LLC	P2	B (57)
Pembrolizumab/Vibostolimab Coformulation Urinary Bladder Neoplasm	Merck Sharp & Dohme LLC	P2	B (57)
Pertuzumab Urinary Bladder Neoplasm	Cancer Research UK	P2/3	B (57)
Trastuzumab Urinary Bladder Neoplasm	Cancer Research UK	P2/3	B (57)
Oxaliplatin Urinary Bladder Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (55)
Ipilimumab Urinary Bladder Neoplasm	Dana-Farber Cancer Institute	P2	CCC (53)
Atezolizumab Urinary Bladder Neoplasm	Cancer Research UK	P1/2	CCC (48)
azd8853 Urinary Bladder Neoplasm	AstraZeneca	P1/2	CCC (48)
htl0039732 capsules Urinary Bladder Neoplasm	Cancer Research UK	P1/2	CCC (48)
Zelenectide Pavedotin Urinary Bladder Neoplasm	BicycleTx Limited	P1/2	CCC (48)
Zirconium Zr 89 Crefmirlimab Berdoxam Urinary Bladder Neoplasm	AstraZeneca	P1/2	CCC (48)
Loxo-435 Urinary Bladder Neoplasm	Eli Lilly and Company	P1	CC (43)
ly4052031 Urinary Bladder Neoplasm	Eli Lilly and Company	P1	CC (43)
ly4101174 Urinary Bladder Neoplasm	Eli Lilly and Company	P1	CC (43)
Sigvotatug Vedotin Urinary Bladder Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (43)
Zirconium Zr 89-Dfo-Ys5 Urinary Bladder Neoplasm	Robert Flavell, MD, PhD	P1	CC (43)